Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-PEDS tirzepatide in pediatric type 2 diabetes
MOH_2022-06-07_011840Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Started May 2022; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2022-06-07_011840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-07_011840.